Delivery Order HHSN272201100021I-HHSN27200038
Award Date 9/19/16
Potential Completion Date 9/30/19
Potential Value $1.5M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued at $1,826,332.06, is for the provision of preclinical development support services related to the NIAID's infectious disease research and product development...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a large for-profit manufacturer of goods. The contract, titled "ESSENTIAL CORE ACTIVITIES III," has a ceiling value of $1,920,166.00 and an ultimate completion date of June 8, 2029. This contract is not set aside for any specific business...
- This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...
- This federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), is valued at $79,489.53. The contract was awarded to the prime contractor, Advanced Bioscience Laboratories, Inc. (ABL), to assist NIAID in planning and implementing two consultations focused on quality management systems and quality risk management for NIAID contractors and extramural programmatic staff. The contract has no set-aside...
- This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The $9,967,500.00 cost-plus-fixed-fee contract supports NIAID's Preclinical Development program, specifically the production of the MHRP GP145 Clade C trimer protein. This contract does not have a set-aside designation. ABL, a for-profit manufacturer of goods, has been...
- This federal contract award is for the PRODUCTION OF ADJUVANTS by Advanced Bioscience Laboratories, Inc. (ABL), a for-profit organization and manufacturer of goods. The contract, valued at $1,458,936.50, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, with an ultimate completion...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract, valued at $835,962.00, is for preclinical development support, specifically the production of the GEO-D02 DNA drug product. This is a cost-plus-fixed-fee delivery order contract with a period of performance ending on February 28, 2022. The contract does not have a...
- This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $173,773 award is for a base task order under a larger Indefinite Delivery Vehicle (IDV) valued at $534,190.43. The contract is for the manufacture and characterization of vaccines, with a period of performance ending on May 14, 2028. The contract is cost-plus-fixed-fee and does not...
- This is a prime contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) on September 20, 2017. The contract has a potential value of $2,044,103.00 and is a Delivery Order for NIAID Preclinical Development Support services. The contract has a completion date of December 31, 2022 and is not set-aside. ABL is a contract research and...